New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
13:48 EDTSTJSt. Jude Medical expects to acquire rest of CardioMEMS in Q2
St. Jude Medical and CardioMEMS confirmed FDA approval of the CardioMEMS HF System. The CardioMEMS HF System is the first and only FDA-approved heart failure monitoring device that has been proven to significantly reduce HF hospital admissions when used by physicians to manage heart failure. In September 2010, St. Jude Medical invested $60M for 19% ownership of CardioMEMS, with an exclusive option to purchase the remaining 81% of the company for $375M. St. Jude Medical now intends to immediately exercise its exclusive option to acquire CardioMEMS, and expects to complete the acquisition in Q2.
News For STJ From The Last 14 Days
Check below for free stories on STJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
05:15 EDTSTJData shows PA pressure monitoring did not adversely affect kidney function
Subscribe for More Information
September 15, 2014
08:02 EDTSTJSt. Jude Medical announces launch of OPTISTM integrated system
St. Jude Medical announced the company has secured CE Mark and FDA clearance for the new OPTISTM Integrated System. The system is a departure from traditional, mobile cart-based diagnostic tools and advances percutaneous coronary intervention optimization via direct installation into a hospitalís cardiac catheterization laboratory, fully integrating optical coherence tomography and fractional flow reserve into PCI workflow.
07:45 EDTSTJCardiovascular Research Foundation to hold a conference
Transcatheter Cardiovascular Therapeutics: TCT 2014 to be held in Washington, D.C. on September 13-17 with some presentations being webcasted. Webcast Link
07:21 EDTSTJHeart Failure Society of America to hold annual meeting
Subscribe for More Information
September 13, 2014
18:16 EDTSTJSt. Jude Medical announces data from the EnligHTN III study
St. Jude Medical announced 12-month outcome data from the EnligHTN III study, which demonstrated a continuation of safe, rapid and effective treatment with the next-generation EnligHTN Renal Denervation System for patients with drug-resistant, uncontrolled hypertension. The results were presented during the 26th annual Transcatheter Cardiovascular Therapeutics scientific symposium.
September 12, 2014
15:03 EDTSTJSt. Jude Medical pausing Portico sales, implants, says Wells Fargo
Subscribe for More Information
September 8, 2014
07:26 EDTSTJMorgan Stanley to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use